Panacea Acquisition Stock Quote NUVB - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.585

Bid

Ask

Volume

1,538,856

2.50 Day's Range 2.65

1.43 52 Week Range 4.1598

Market Cap

870.024M

Previous Close

2.67

Open

2.64

Last Trade

300

2.585

Last Trade Time

14:46:41

Financial Volume

$ 3,940,983

VWAP

2.561

Average Volume (3m)

2,447,061

Shares Outstanding

336,566,525

Dividend Yield

PE Ratio

-11.41

Earnings Per Share (EPS)

-0.23

Revenue

Net Profit

-75.8M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ecor1cap.com

Headquarters

Wilmington, Delaware, USA

Founded

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was $2.67. Over the last year, Panacea Acquisition shares have traded in a share price range of $ 1.43 to $ 4.1598.

Panacea Acquisition currently has 336,566,525 shares outstanding. The market capitalization of Panacea Acquisition is $898.63 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -11.41.

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief...

Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Taletrectinib will be marketed in China by Innovent Biologics Approval is based on the pivotal Phase 2 TRUST-I study, demonstrating taletrectinib's durable responses and prolonged...

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that demonstrated durable responses and prolonged progression-free...

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration PR Newswire SAN FRANCISCO and SUZHOU, China, Dec. 20...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.375	-12.6689189189	2.96	3.455	2.44	4376164	3.01347326	CS
4	-0.115	-4.25925925926	2.7	3.455	2.44	3031169	2.81524206	CS
12	0.225	9.53389830508	2.36	3.455	2.18	2447061	2.73936537	CS
26	-0.875	-25.289017341	3.46	3.97	2	1937532	2.7876724	CS
52	0.945	57.6219512195	1.64	4.1598	1.43	1646419	2.82718999	CS
156	-3.295	-56.037414966	5.88	6.23	0.95	1101316	2.72202282	CS
260	-7.415	-74.15	10	15.23	0.95	1048651	4.22724469	CS

NUVB - Frequently Asked Questions (FAQ)

What is the current Panacea Acquisition share price?

The current share price of Panacea Acquisition is $ 2.585

How many Panacea Acquisition shares are in issue?

Panacea Acquisition has 336,566,525 shares in issue

What is the market cap of Panacea Acquisition?

The market capitalisation of Panacea Acquisition is USD 898.63M

What is the 1 year trading range for Panacea Acquisition share price?

Panacea Acquisition has traded in the range of $ 1.43 to $ 4.1598 during the past year

What is the PE ratio of Panacea Acquisition?

The price to earnings ratio of Panacea Acquisition is -11.41

What is the reporting currency for Panacea Acquisition?

Panacea Acquisition reports financial results in USD

What is the latest annual profit for Panacea Acquisition?

The latest annual profit of Panacea Acquisition is USD -75.8M

What is the registered address of Panacea Acquisition?

The registered address for Panacea Acquisition is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Panacea Acquisition website address?

The website address for Panacea Acquisition is ecor1cap.com

Which industry sector does Panacea Acquisition operate in?

Panacea Acquisition operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
STEMStem Inc	$ 0.8387 (24.45%)	45.76M
QBTSD Wave Quantum Inc	$ 4.74 (23.76%)	112.33M
BEDUBright Scholar Education Holdings Limited	$ 1.76 (19.73%)	3.76k
HOVHovnanian Enterprises Inc	$ 133.5198 (11.69%)	76.9k
EQSEquus Total Return Inc	$ 1.21 (11.01%)	9.57k
SIGSignet Jewelers Ltd	$ 58.045 (-21.60%)	7.91M
SESSES AI Corporation	$ 0.80155 (-14.73%)	27.94M
ARDTArdent Health Partners Inc	$ 14.29 (-10.97%)	438.07k
LITBLightInTheBox Holding Co Ltd	$ 1.13 (-10.32%)	10.96k
FUBOfuboTV	$ 4.015 (-9.78%)	52.54M
QBTSD Wave Quantum Inc	$ 4.74 (23.76%)	112.33M
FUBOfuboTV	$ 4.015 (-9.78%)	52.54M
STEMStem Inc	$ 0.8387 (24.45%)	45.76M
BBDBanco Bradesco SA	$ 1.935 (2.38%)	45.05M
IONQIonQ Inc	$ 29.94 (7.47%)	35.57M